IRIS
DANESE, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.646
EU - Europa 3.711
AS - Asia 1.824
AF - Africa 606
Continente sconosciuto - Info sul continente non disponibili 44
SA - Sud America 42
OC - Oceania 40
Totale 26.913
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.460
FI - Finlandia 1.007
SG - Singapore 978
IE - Irlanda 703
NG - Nigeria 592
CN - Cina 518
FR - Francia 402
DE - Germania 383
NL - Olanda 222
GB - Regno Unito 206
IT - Italia 195
SE - Svezia 185
CA - Canada 174
TR - Turchia 99
BE - Belgio 80
IL - Israele 69
RU - Federazione Russa 61
IN - India 60
RO - Romania 46
A2 - ???statistics.table.value.countryCode.A2??? 41
CL - Cile 35
AU - Australia 34
ES - Italia 34
PL - Polonia 34
CZ - Repubblica Ceca 29
JP - Giappone 27
UA - Ucraina 26
GR - Grecia 23
IR - Iran 23
AT - Austria 16
NO - Norvegia 16
BD - Bangladesh 11
CH - Svizzera 9
MD - Moldavia 9
EG - Egitto 8
HK - Hong Kong 8
MX - Messico 8
DK - Danimarca 7
NZ - Nuova Zelanda 6
AE - Emirati Arabi Uniti 5
BR - Brasile 4
IQ - Iraq 4
MY - Malesia 4
SA - Arabia Saudita 4
EU - Europa 3
GT - Guatemala 3
HU - Ungheria 3
MO - Macao, regione amministrativa speciale della Cina 3
PT - Portogallo 3
AL - Albania 2
KR - Corea 2
MK - Macedonia 2
TN - Tunisia 2
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
ID - Indonesia 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LV - Lettonia 1
MT - Malta 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 26.913
Salva come PNG Salva come JPEG
Città #
Chandler 4.195
Wilmington 4.032
San Mateo 1.633
Ann Arbor 1.257
Helsinki 1.007
Lawrence 712
Princeton 712
Leawood 703
Dublin 700
Boardman 697
Singapore 653
Benin City 589
Ashburn 492
Shanghai 461
Paris 388
New York 387
Woodbridge 378
Fairfield 364
Amsterdam 212
London 153
Toronto 143
Seattle 117
Norwalk 103
San Diego 93
Kocaeli 92
Phoenix 78
Brussels 74
Milan 66
Redwood City 46
Santa Clara 42
Monmouth Junction 36
Los Angeles 35
Falls Church 34
Abbiategrasso 33
Clearwater 33
Pune 33
Cambridge 29
Houston 25
Moscow 25
Brno 24
Des Moines 24
Redmond 21
Falkenstein 19
Tappahannock 17
Las Vegas 13
Munich 12
Warsaw 12
Beijing 11
Gunzenhausen 11
Raleigh 11
Andover 9
Chisinau 9
Duncan 9
Hanover 9
La Canada Flintridge 9
Novokuznetsk 9
St Louis 9
Vienna 9
Dallas 8
Kemerovo 8
Buffalo 7
Cairo 7
Sacramento 7
Zhengzhou 7
Cupertino 6
Henderson 6
Reghin 6
Tokyo 6
Valencia 6
Leipzig 5
Ottawa 5
Pitesti 5
Saint Louis 5
Sunderland 5
Sydney 5
Washington 5
Winnipeg 5
Apo 4
Athens 4
Auckland 4
Genoa 4
Glasgow 4
Hangzhou 4
Istanbul 4
Köln 4
Madrid 4
Melbourne 4
Mumbai 4
Saint Paul 4
San Pedro 4
Vancouver 4
Adliswil 3
Alexandria 3
Augusta 3
Berlin 3
Chennai 3
Collegeville 3
Columbus 3
Groningen 3
Guatemala City 3
Totale 21.306
Salva come PNG Salva come JPEG
Nome #
Biological agents for ulcerative colitis : Hypes and hopes 255
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion 180
Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial 153
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 83
Crohn's disease 82
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (R) (Cortiment (R)(MMX (R))) for active, mild-to-moderate ulcerative colitis 77
Evolving strategies and goals of treatment in ulcerative colitis 72
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease 71
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 70
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer 69
Adalimumab in ulcerative colitis: Ready for prime time 69
Laparoscopic Surgery for Recurrent Crohn's Disease 68
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response 67
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment 66
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 66
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice 65
Thrombomodulin-activated protein C-endothelial protein C receptor pathway: A novel anti-inflammatory system in IBD 65
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 64
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 64
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 63
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease 63
IBD Of mice and men-shedding new light on IL-13 activity in IBD 61
A NEW TOOL FOR PRE-COLONOSCOPY DYING OF THE COLONIC MUCOSA WITH ORAL MULTI MATRIX RELEASE TECHNOLOGY (MMX (R))-RELEASED METHYLENE BLUE: A PRELIMINARY STUDY 60
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis 60
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. 60
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 59
Association between Helicobacter pylori CagA-positive strains and ischemic stroke. 59
Methotrexate for Corticosteroid- Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial 59
Colitis-associated cancer: the dark side of inflammatory bowel disease 59
Dysregulated intracellular redox equilibrium in intestinal lamina propria T cells (LPT) contributes to mucosal inflammation 58
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 58
Effect of Tumor Necrosis Factor-alpha Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease 58
Budesonide : teaching an old dog new tricks for inflammatory bowel disease treatment 57
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients 57
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 57
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 57
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 57
JAK inhibitors: Novel developments in management of ulcerative colitis 57
Ulcerative Colitis 57
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer 57
Adalimumab in active ulcerative colitis: A "real-life" observational study 57
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 56
Balanced propofol sedation administered by nonanesthesiologists : the first Italian experience 56
Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis 56
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 56
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations 55
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 55
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 55
Risk of postoperative recurrence and postoperative management of Crohn's disease 55
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 55
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 55
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis 55
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study 55
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 55
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease 55
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 54
Surgical rates in the era of biological therapy: up, down or unchanged? 54
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? 54
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 54
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 54
Correlation between delta(CO2)-C-13 excretion and prevalence of dyspeptic symptoms in subjects evaluated for H. pylori infection by C-13-urea breath test 54
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 54
WallFlex colonic stent placement for management of malignant colonic obstruction : a prospective study at two centers 54
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 54
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 53
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 53
Enhanced platelet adhesion induces angiogenesis in the IBD microcirculation 53
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 53
Microscopic features of colorectal neoplasia in inflammatory bowel diseases 53
Editorial: to facitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply 53
Ustekinumab in the management of Crohn's disease: Expert opinion 53
Helicobacter pylori infection in rheumatoid arthritis - Reply 53
When can unfractionated heparin really be useful in the treatment of ulcerative colitis? 53
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 53
Stopping infliximab in crohn's disease: Still an ongoing STORI 53
Effect of Oral Administration of Methylene Blue MMx (R) Tablets on Double-Stranded DNA Damage Assessed by gamma H2AX Analysis of Colon Biopsy Samples - A Single Center, Open Label, Safety, Phase II Study 53
Association between Helicobacter pylori cytotoxic type I strains and migraine with aura 53
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 53
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach 53
Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go 53
Is cytotoxic-associated gene A-positive Helicobacter pylori important? 52
Biological therapies for inflammatory bowel disease: Research drives clinics 52
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease 52
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 52
High prevalence of infection by H. pylori cytotoxic type I strains in recurrent spontaneous abortion 52
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses 52
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 52
The CD40/CD40L costimulatory pathway in inflammatory bowel disease 52
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis 52
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 52
Clinical development of biologicals and biosimilars - safety concerns 52
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 52
Regulation of leukocyte recruitment by the long pentraxin PTX3. 52
Emerging therapeutic targets and strategies in Crohn's disease 51
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) 51
Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? 51
The nocebo effect: a clinical challenge in the era of biosimilars 51
Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects 51
Accuracy of a new diagnostic tool in deep infiltrating endometriosis: Positron emission tomography-computed tomography with 16 alpha-[18F]fluoro-17 beta-estradiol 51
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 51
Totale 6.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 214.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202094 0 0 0 0 0 0 0 0 0 0 2 92
2020/20217.428 40 114 49 76 36 2.221 1.007 529 1.484 982 25 865
2021/20224.321 216 55 132 871 39 48 127 555 391 708 944 235
2022/202310.520 1.606 443 1.059 1.208 899 954 32 942 1.829 866 553 129
2023/20245.140 439 531 1.151 220 179 616 231 277 98 90 424 884
2024/2025108 108 0 0 0 0 0 0 0 0 0 0 0
Totale 27.611